Coeptis Therapeutics (NASDAQ:COEP) versus Solid Biosciences (NASDAQ:SLDB) Financial Comparison

Coeptis Therapeutics (NASDAQ:COEP) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Risk and Volatility

Coeptis Therapeutics has a beta of -0.82, meaning that its share price is 182% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Profitability

This table compares Coeptis Therapeutics and Solid Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-1,094.50%	-219.97%
Solid Biosciences	N/A	-58.75%	-47.84%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Coeptis Therapeutics and Solid Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	1	0	0	2.00
Solid Biosciences	0	0	9	4	3.31

Solid Biosciences has a consensus target price of $15.30, suggesting a potential upside of 279.65%. Given Solid Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Coeptis Therapeutics.

Institutional and Insider Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 13.6% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Coeptis Therapeutics and Solid Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$21.27 million	($5.80)	-2.15
Solid Biosciences	$8.09 million	19.90	-$96.01 million	($3.04)	-1.33

Coeptis Therapeutics has higher earnings, but lower revenue than Solid Biosciences. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Solid Biosciences beats Coeptis Therapeutics on 11 of the 13 factors compared between the two stocks.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

About Solid Biosciences

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.